StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.6
Power Rank trend -> Rising
10/08/2024 10:42:00 EST
Adaptive Biotechnologies Corp (ADPT)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, ADPT has been trading in a range between $5.14 and $4.00 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
ADPT is breaking above top of the recent 20 day range at $5.14 and appears that it could have some more upside. If it enters a yellow zone the trend may be faltering - consider exiting or taking profits. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Adaptive Biotechnologies Corp $ADPT entered a Green zone 123 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $12.14, a potential upside of 124.4% from the recent price of 5.41. The stock is trading 7.21% (potential upside) below its 52 week high of $5.80 and 137.28 % (potential downside) above its 52 week low of $2.28 - based on the recent price.
Company Summary
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).
News
| Adaptive Announces IVDR Certification for clonoSEQ® in European Union clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies Source: GlobeNewsWire Thu, 29 Aug 2024 07:30:00 -0400 Sentiment: Neutral |
| Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. Source: GlobeNewsWire Thu, 22 Aug 2024 16:03:00 -0400 Sentiment: Neutral |
| Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Karina Calzadilla – Head-Investor Relations Chad Robins – Chief Executive Officer and Co-Founder Kyle Piskel – Chief Financial Officer Susan Bobulsky – Chief Commercial Officer-MRD Conference Call Participants Mark Massaro – BTIG David Westenberg – Piper Sandler Tejas Savant – Morgan Stanley Dan Brennan – TD Cowen Andrew Brackmann – William Blair Rachel Vatnsdal – JPMorgan Sung Ji Nam – Scotiabank Operator Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2024 Earnings Call. Source: Seeking Alpha Thu, 01 Aug 2024 22:25:25 -0400 Sentiment: Neutral |
| Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Source: Zacks Investment Research Thu, 01 Aug 2024 20:00:28 -0400 Sentiment: Positive |
| Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago. Source: Zacks Investment Research Thu, 01 Aug 2024 19:20:25 -0400 Sentiment: Negative |
Technicals 52 Week Hi: 5.795 52 Week Low: 2.28 Beta: 1.437 50 Day MA: 4.5838 200 Day MA: 3.8787 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: -0.117 Forward PE: 0 Trailing PE: 0